Translational Geroscience Network to Accelerate Aging-Based Therapies
Official title: Translational Geroscience Network
Funded at Cedars-Sinai Medical Center · NIH-11417303 · Data updated 2026-11-12
A nationwide effort aims to speed up testing of aging-focused lifestyle, nutritional, and drug strategies to prevent or treat age-related diseases in adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | February 1, 2019 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $702,201 |
| NIH project number | 5R33AG061456-08 |
| Project ID | NIH-11417303 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults who may participate in early-phase gerotherapeutic clinical studies or contribute data and biospecimens for aging-related research.
✕Less likely to help
Individuals not eligible for early-phase aging intervention trials or without age-related conditions may not directly benefit.
What this research studies
The Translational Geroscience Network (TGN) is a nationwide program that seeks to move promising aging interventions from basic science into human testing. It focuses on interventions that target core aging processes, including lifestyle changes, nutrition, and drugs like metformin or anti-inflammatories, and aims to validate them in early clinical studies. The network provides design guidance, regulatory support, data management, and biobanking to enable safe and efficient human trials. By broadening the portfolio of gerotherapeutic approaches, TGN hopes to delay or reduce multiple age-related illnesses in adults.
Why it matters
Potential benefit: If successful, this work could lead to new, broadly applicable strategies to improve health span and reduce the burden of age-related diseases.
How similar studies have gone: Previous geroscience efforts have shown signals of safety and biological effects in early trials, with ongoing exploration in humans.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Kirkland, James L. — Cedars-Sinai Medical Center
- Study coordinator: Kirkland, James L.
Related research
Other NIH-funded projects on the same topics.
-
Lipid signals that control acetyl-CoA and fat metabolism in NAFLD
A study exploring how membrane lipids influence acetyl-CoA metabolism to understand and potentially treat nonalcoholic fatty liver disease (NAFLD).
-
Them1’s role in fat metabolism and MASLD progression
Aims to understand how a fat-regulating protein (Them1) affects energy use in fat and liver, and how this could contribute to MASLD in people who are overweight.
-
Biomarker-guided Immunosuppression in Kidney Transplant Patients
A multicenter study in kidney transplant recipients is testing whether a biomarker score from HLA-DR/DQ can guide changes in immunosuppression to reduce rejection risk and drug toxicity.
-
Alpha5 integrin's role in ALS: how a cell switch worsens disease
Aims to understand how a specific protein called alpha5 integrin in immune cells affects ALS progression and whether blocking it can help extend life.
-
Chlamydia pneumoniae infection and Alzheimer's disease progression
This project looks at whether a common lung infection, Chlamydia pneumoniae, might influence Alzheimer's disease in people and what that could mean for treatment.
-
Them1 Inhibitors to Help Treat Fatty Liver Disease
Aims to develop and test small molecule drugs that block Them1 to help people with non-alcoholic fatty liver disease (NAFLD).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.